Background: A prophylactic quadrivalent human papillomavirus (HPV) vaccine could benefit
adult women if they are susceptible to incident genital HPV infections and are acquiring new …

Background Infection with human papillomavirus (HPV) and diseases caused by HPV are
common in boys and men. We report on the safety of a quadrivalent vaccine (active against …

Objectives The natural history of human papillomavirus (HPV) infection has been studied
extensively in young women; this study investigated HPV infection in adult women. Methods …

Quadrivalent human papillomavirus (HPV) vaccine has been shown to provide protection
from HPV 6/11/16/18–related cervical, vaginal, and vulvar disease through 3 years. We …

Objective In the quadrivalent (types 6/11/16/18) HPV vaccine (GARDASIL®/SILGARD®)
clinical program, 73% of women aged 16-26 were naïve to all vaccine HPV types. In these …

Background The impact of the prophylactic vaccine against human papillomavirus (HPV)
types 6, 11, 16, and 18 (HPV6/11/16/18) on all HPV-associated genital disease was …

OBJECTIVE: The purpose of this study was to inform policy regarding human papillomavirus
(HPV) vaccination in North America. We measured the clinical impact of HPV-6/-11/-16/-18 …

HPV‐related diseases affect anogenital and oropharyngeal regions, heavily affecting the
psychosexual dimension of both male and female individuals. HPV vaccination programs …

Background A phase 3 trial was conducted to evaluate the efficacy of a prophylactic
quadrivalent vaccine in preventing anogenital diseases associated with human …

ABSTRACT Background: In Phase II/III trials, administration of quadrivalent human
papillomavirus (HPV)(types 6/11/16/18) L1 virus-like-particle vaccine was highly effective in …